| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 187 | 2025 | 952 | 33.840 |
Why?
|
| Homosexuality, Male | 124 | 2023 | 332 | 24.650 |
Why?
|
| Pre-Exposure Prophylaxis | 55 | 2024 | 186 | 16.780 |
Why?
|
| Sexual and Gender Minorities | 63 | 2025 | 250 | 13.750 |
Why?
|
| Social Networking | 42 | 2025 | 85 | 10.150 |
Why?
|
| Anti-HIV Agents | 31 | 2025 | 193 | 9.910 |
Why?
|
| Sexual Behavior | 60 | 2025 | 328 | 8.580 |
Why?
|
| Transgender Persons | 23 | 2025 | 113 | 7.710 |
Why?
|
| Social Support | 28 | 2025 | 231 | 5.890 |
Why?
|
| Chicago | 72 | 2025 | 1452 | 5.690 |
Why?
|
| Young Adult | 119 | 2025 | 6922 | 4.730 |
Why?
|
| Risk-Taking | 35 | 2021 | 158 | 4.280 |
Why?
|
| Syphilis | 10 | 2023 | 35 | 4.110 |
Why?
|
| Contact Tracing | 12 | 2023 | 29 | 4.060 |
Why?
|
| Male | 212 | 2025 | 44355 | 3.940 |
Why?
|
| Adolescent | 97 | 2025 | 9550 | 3.710 |
Why?
|
| Disease Transmission, Infectious | 11 | 2019 | 56 | 3.660 |
Why?
|
| Sexual Partners | 25 | 2024 | 103 | 3.640 |
Why?
|
| Substance-Related Disorders | 15 | 2025 | 440 | 3.610 |
Why?
|
| Adult | 165 | 2025 | 27849 | 3.520 |
Why?
|
| Patient Acceptance of Health Care | 18 | 2025 | 290 | 3.420 |
Why?
|
| Unsafe Sex | 17 | 2023 | 45 | 3.130 |
Why?
|
| Humans | 269 | 2025 | 93132 | 3.090 |
Why?
|
| Sexually Transmitted Diseases | 14 | 2023 | 109 | 3.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 26 | 2022 | 557 | 2.960 |
Why?
|
| Opioid-Related Disorders | 14 | 2025 | 234 | 2.850 |
Why?
|
| Continuity of Patient Care | 9 | 2021 | 173 | 2.700 |
Why?
|
| Residence Characteristics | 12 | 2024 | 212 | 2.650 |
Why?
|
| Social Stigma | 15 | 2025 | 88 | 2.640 |
Why?
|
| Viral Load | 11 | 2024 | 154 | 2.450 |
Why?
|
| Medication Adherence | 8 | 2022 | 120 | 2.370 |
Why?
|
| Peer Group | 7 | 2025 | 90 | 2.210 |
Why?
|
| HIV-1 | 9 | 2025 | 173 | 2.160 |
Why?
|
| Social Media | 8 | 2025 | 111 | 2.130 |
Why?
|
| Acquired Immunodeficiency Syndrome | 7 | 2023 | 67 | 2.010 |
Why?
|
| Safe Sex | 7 | 2020 | 23 | 1.980 |
Why?
|
| Criminals | 4 | 2024 | 34 | 1.970 |
Why?
|
| Health Promotion | 10 | 2020 | 170 | 1.950 |
Why?
|
| Female | 107 | 2025 | 48542 | 1.910 |
Why?
|
| United States | 48 | 2025 | 7581 | 1.750 |
Why?
|
| Papillomavirus Infections | 8 | 2022 | 301 | 1.700 |
Why?
|
| HIV Seropositivity | 8 | 2020 | 49 | 1.690 |
Why?
|
| Cross-Sectional Studies | 27 | 2025 | 1849 | 1.550 |
Why?
|
| Middle Aged | 70 | 2025 | 27535 | 1.490 |
Why?
|
| Cohort Studies | 23 | 2025 | 3044 | 1.490 |
Why?
|
| Internet | 7 | 2021 | 345 | 1.430 |
Why?
|
| Circumcision, Male | 5 | 2013 | 19 | 1.410 |
Why?
|
| Public Opinion | 4 | 2025 | 50 | 1.390 |
Why?
|
| Marijuana Use | 2 | 2025 | 11 | 1.370 |
Why?
|
| Socioeconomic Factors | 16 | 2023 | 627 | 1.330 |
Why?
|
| India | 17 | 2018 | 141 | 1.310 |
Why?
|
| Health Status Disparities | 6 | 2020 | 218 | 1.300 |
Why?
|
| Drug Overdose | 6 | 2025 | 89 | 1.280 |
Why?
|
| Automobile Driving | 5 | 2014 | 33 | 1.270 |
Why?
|
| Surveys and Questionnaires | 27 | 2025 | 2787 | 1.260 |
Why?
|
| Criminal Law | 5 | 2023 | 14 | 1.250 |
Why?
|
| Logistic Models | 17 | 2020 | 1240 | 1.240 |
Why?
|
| Referral and Consultation | 6 | 2021 | 373 | 1.230 |
Why?
|
| Condoms | 7 | 2019 | 37 | 1.150 |
Why?
|
| Risk Factors | 25 | 2023 | 5900 | 1.140 |
Why?
|
| Longitudinal Studies | 17 | 2025 | 1160 | 1.140 |
Why?
|
| Crime | 4 | 2024 | 38 | 1.120 |
Why?
|
| Anus Neoplasms | 3 | 2019 | 37 | 1.050 |
Why?
|
| Health Services Accessibility | 9 | 2025 | 480 | 1.030 |
Why?
|
| Coinfection | 4 | 2023 | 67 | 1.020 |
Why?
|
| Prevalence | 19 | 2024 | 1318 | 1.010 |
Why?
|
| Marijuana Abuse | 2 | 2025 | 29 | 1.000 |
Why?
|
| Cell Phone | 4 | 2018 | 39 | 0.990 |
Why?
|
| Substance Abuse, Intravenous | 7 | 2021 | 66 | 0.990 |
Why?
|
| HIV Seronegativity | 3 | 2020 | 12 | 0.990 |
Why?
|
| Stress, Psychological | 6 | 2021 | 343 | 0.940 |
Why?
|
| Epidemics | 4 | 2023 | 41 | 0.930 |
Why?
|
| Motor Vehicles | 4 | 2012 | 19 | 0.900 |
Why?
|
| Family Relations | 2 | 2016 | 37 | 0.870 |
Why?
|
| Incidence | 13 | 2022 | 1697 | 0.870 |
Why?
|
| Cooperative Behavior | 3 | 2023 | 191 | 0.860 |
Why?
|
| Violence | 2 | 2018 | 151 | 0.830 |
Why?
|
| HIV | 8 | 2022 | 46 | 0.830 |
Why?
|
| Cannabis | 2 | 2023 | 38 | 0.820 |
Why?
|
| Health Equity | 2 | 2024 | 101 | 0.820 |
Why?
|
| Exposure to Violence | 3 | 2024 | 14 | 0.810 |
Why?
|
| Communication | 4 | 2025 | 433 | 0.810 |
Why?
|
| Herpes Genitalis | 3 | 2015 | 8 | 0.790 |
Why?
|
| Health Surveys | 8 | 2019 | 245 | 0.790 |
Why?
|
| Authorship | 1 | 2023 | 26 | 0.780 |
Why?
|
| Hand Disinfection | 2 | 2021 | 18 | 0.770 |
Why?
|
| Drug Users | 5 | 2025 | 29 | 0.760 |
Why?
|
| Risk Assessment | 8 | 2021 | 2434 | 0.760 |
Why?
|
| Papillomaviridae | 4 | 2022 | 179 | 0.750 |
Why?
|
| Rural Population | 8 | 2025 | 170 | 0.720 |
Why?
|
| Skin Pigmentation | 2 | 2019 | 36 | 0.720 |
Why?
|
| Social Capital | 2 | 2021 | 3 | 0.720 |
Why?
|
| Social Work | 2 | 2019 | 20 | 0.710 |
Why?
|
| Gambling | 1 | 2025 | 168 | 0.700 |
Why?
|
| Viremia | 1 | 2021 | 51 | 0.700 |
Why?
|
| Urban Population | 5 | 2018 | 234 | 0.690 |
Why?
|
| Pandemics | 14 | 2024 | 873 | 0.690 |
Why?
|
| Sexuality | 1 | 2021 | 40 | 0.690 |
Why?
|
| Masks | 1 | 2021 | 31 | 0.680 |
Why?
|
| Ambulatory Care Facilities | 3 | 2020 | 117 | 0.680 |
Why?
|
| Interpersonal Relations | 4 | 2020 | 174 | 0.680 |
Why?
|
| Travel | 2 | 2018 | 73 | 0.680 |
Why?
|
| Motivation | 4 | 2019 | 310 | 0.680 |
Why?
|
| Anus Diseases | 2 | 2022 | 16 | 0.670 |
Why?
|
| Racism | 3 | 2019 | 103 | 0.660 |
Why?
|
| Sleep Wake Disorders | 1 | 2022 | 124 | 0.660 |
Why?
|
| Trust | 5 | 2025 | 97 | 0.660 |
Why?
|
| Gender Identity | 5 | 2025 | 56 | 0.650 |
Why?
|
| Emergency Service, Hospital | 4 | 2023 | 576 | 0.650 |
Why?
|
| Health Status | 4 | 2021 | 373 | 0.650 |
Why?
|
| Bisexuality | 6 | 2020 | 36 | 0.630 |
Why?
|
| Drug Prescriptions | 2 | 2020 | 150 | 0.630 |
Why?
|
| Health Behavior | 5 | 2023 | 182 | 0.620 |
Why?
|
| Resilience, Psychological | 1 | 2020 | 35 | 0.620 |
Why?
|
| Primary Prevention | 1 | 2020 | 87 | 0.620 |
Why?
|
| Electronic Health Records | 5 | 2023 | 373 | 0.620 |
Why?
|
| Communicable Disease Control | 3 | 2022 | 55 | 0.600 |
Why?
|
| Delivery of Health Care | 3 | 2019 | 449 | 0.580 |
Why?
|
| Analgesics, Opioid | 8 | 2025 | 515 | 0.570 |
Why?
|
| Sex Workers | 2 | 2021 | 9 | 0.560 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2017 | 62 | 0.560 |
Why?
|
| Texas | 7 | 2022 | 131 | 0.560 |
Why?
|
| Heterosexuality | 1 | 2018 | 20 | 0.560 |
Why?
|
| Patient Compliance | 4 | 2021 | 236 | 0.560 |
Why?
|
| Aged | 19 | 2025 | 20395 | 0.550 |
Why?
|
| Healthcare Disparities | 5 | 2019 | 496 | 0.550 |
Why?
|
| Models, Psychological | 2 | 2016 | 164 | 0.540 |
Why?
|
| Epidemiologic Methods | 1 | 2018 | 60 | 0.540 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 22 | 0.530 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 396 | 0.530 |
Why?
|
| Illinois | 8 | 2024 | 515 | 0.520 |
Why?
|
| Reproductive Health | 1 | 2018 | 33 | 0.520 |
Why?
|
| Mass Screening | 7 | 2021 | 706 | 0.520 |
Why?
|
| Greece | 8 | 2022 | 20 | 0.520 |
Why?
|
| Text Messaging | 2 | 2015 | 34 | 0.510 |
Why?
|
| Anti-Retroviral Agents | 4 | 2018 | 35 | 0.500 |
Why?
|
| Uncertainty | 1 | 2017 | 78 | 0.500 |
Why?
|
| Louisiana | 4 | 2020 | 18 | 0.500 |
Why?
|
| Penile Neoplasms | 1 | 2016 | 19 | 0.490 |
Why?
|
| Health Care Reform | 1 | 2017 | 77 | 0.490 |
Why?
|
| Tenofovir | 3 | 2022 | 14 | 0.470 |
Why?
|
| Urban Health | 2 | 2013 | 54 | 0.470 |
Why?
|
| Pharmaceutical Preparations | 3 | 2022 | 99 | 0.460 |
Why?
|
| Pilot Projects | 4 | 2024 | 913 | 0.460 |
Why?
|
| Mother-Child Relations | 1 | 2015 | 30 | 0.460 |
Why?
|
| Central Nervous System Stimulants | 3 | 2023 | 233 | 0.450 |
Why?
|
| Psychoanalytic Theory | 1 | 2015 | 2 | 0.450 |
Why?
|
| Psychoanalytic Therapy | 1 | 2015 | 3 | 0.450 |
Why?
|
| Chemoprevention | 1 | 2015 | 93 | 0.440 |
Why?
|
| Group Processes | 1 | 2015 | 30 | 0.440 |
Why?
|
| Geographic Information Systems | 4 | 2024 | 28 | 0.440 |
Why?
|
| Social Identification | 1 | 2015 | 27 | 0.440 |
Why?
|
| Bias | 2 | 2020 | 136 | 0.430 |
Why?
|
| Interviews as Topic | 7 | 2023 | 359 | 0.430 |
Why?
|
| Thinking | 1 | 2015 | 39 | 0.430 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2016 | 149 | 0.430 |
Why?
|
| Self Disclosure | 1 | 2014 | 29 | 0.420 |
Why?
|
| Sociometric Techniques | 1 | 2014 | 3 | 0.420 |
Why?
|
| Women's Health | 1 | 2015 | 107 | 0.420 |
Why?
|
| Multiple Trauma | 1 | 2014 | 37 | 0.420 |
Why?
|
| Spinal Injuries | 1 | 2014 | 28 | 0.420 |
Why?
|
| Patient Participation | 1 | 2016 | 229 | 0.410 |
Why?
|
| Electronic Mail | 1 | 2014 | 15 | 0.410 |
Why?
|
| Transportation | 3 | 2013 | 20 | 0.410 |
Why?
|
| Complementary Therapies | 1 | 2014 | 53 | 0.410 |
Why?
|
| Quality Improvement | 2 | 2017 | 482 | 0.410 |
Why?
|
| Alcohol Drinking | 3 | 2024 | 283 | 0.400 |
Why?
|
| Attitude | 4 | 2023 | 130 | 0.400 |
Why?
|
| Restaurants | 1 | 2013 | 6 | 0.400 |
Why?
|
| Multivariate Analysis | 5 | 2021 | 984 | 0.390 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 317 | 0.390 |
Why?
|
| Decision Making | 2 | 2016 | 671 | 0.390 |
Why?
|
| Depression | 2 | 2022 | 540 | 0.390 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2014 | 112 | 0.380 |
Why?
|
| Comorbidity | 5 | 2023 | 1003 | 0.380 |
Why?
|
| Mexican Americans | 1 | 2013 | 70 | 0.380 |
Why?
|
| Friends | 1 | 2012 | 20 | 0.360 |
Why?
|
| Seroepidemiologic Studies | 4 | 2019 | 56 | 0.360 |
Why?
|
| Retrospective Studies | 9 | 2025 | 10128 | 0.360 |
Why?
|
| Marriage | 1 | 2012 | 23 | 0.360 |
Why?
|
| Program Evaluation | 3 | 2023 | 312 | 0.360 |
Why?
|
| Cervical Vertebrae | 1 | 2014 | 228 | 0.350 |
Why?
|
| Perception | 4 | 2020 | 178 | 0.340 |
Why?
|
| Quality of Health Care | 4 | 2017 | 376 | 0.340 |
Why?
|
| Video Recording | 1 | 2012 | 210 | 0.330 |
Why?
|
| Counseling | 1 | 2012 | 164 | 0.330 |
Why?
|
| Population Dynamics | 1 | 2011 | 144 | 0.320 |
Why?
|
| Prisoners | 2 | 2023 | 47 | 0.320 |
Why?
|
| Risk Reduction Behavior | 4 | 2018 | 100 | 0.320 |
Why?
|
| Health Services Research | 2 | 2008 | 140 | 0.300 |
Why?
|
| Self Efficacy | 2 | 2022 | 58 | 0.300 |
Why?
|
| Poverty | 2 | 2021 | 192 | 0.290 |
Why?
|
| Cities | 5 | 2022 | 57 | 0.290 |
Why?
|
| Hygiene | 1 | 2009 | 9 | 0.290 |
Why?
|
| Papillomavirus Vaccines | 2 | 2021 | 59 | 0.290 |
Why?
|
| Age Factors | 3 | 2018 | 1898 | 0.290 |
Why?
|
| Atherosclerosis | 3 | 2021 | 254 | 0.290 |
Why?
|
| Nitrites | 2 | 2018 | 34 | 0.280 |
Why?
|
| AIDS Serodiagnosis | 2 | 2020 | 26 | 0.280 |
Why?
|
| Sleep | 2 | 2022 | 448 | 0.280 |
Why?
|
| Minority Groups | 2 | 2022 | 149 | 0.270 |
Why?
|
| Male Urogenital Diseases | 1 | 2007 | 7 | 0.270 |
Why?
|
| Gingiva | 1 | 2007 | 7 | 0.270 |
Why?
|
| Cluster Analysis | 4 | 2023 | 391 | 0.270 |
Why?
|
| Alcoholism | 2 | 2020 | 188 | 0.270 |
Why?
|
| Female Urogenital Diseases | 1 | 2007 | 8 | 0.270 |
Why?
|
| AIDS Vaccines | 1 | 2007 | 15 | 0.270 |
Why?
|
| Insurance, Health | 2 | 2020 | 175 | 0.270 |
Why?
|
| Rural Health | 1 | 2007 | 18 | 0.270 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2008 | 72 | 0.260 |
Why?
|
| Sex Work | 3 | 2018 | 12 | 0.260 |
Why?
|
| HIV Antibodies | 1 | 2007 | 38 | 0.260 |
Why?
|
| Cervix Uteri | 1 | 2007 | 73 | 0.260 |
Why?
|
| Attitude to Health | 2 | 2023 | 214 | 0.260 |
Why?
|
| Naloxone | 2 | 2024 | 72 | 0.260 |
Why?
|
| Schools | 2 | 2021 | 84 | 0.250 |
Why?
|
| France | 7 | 2019 | 52 | 0.250 |
Why?
|
| Gift Giving | 1 | 2006 | 4 | 0.250 |
Why?
|
| Odds Ratio | 5 | 2018 | 709 | 0.250 |
Why?
|
| Community-Based Participatory Research | 2 | 2020 | 37 | 0.240 |
Why?
|
| Rilpivirine | 1 | 2025 | 6 | 0.230 |
Why?
|
| Sex Factors | 3 | 2020 | 1102 | 0.230 |
Why?
|
| Drug Industry | 1 | 2006 | 56 | 0.230 |
Why?
|
| Age Distribution | 2 | 2023 | 206 | 0.230 |
Why?
|
| Social Perception | 1 | 2006 | 92 | 0.230 |
Why?
|
| Geography | 2 | 2021 | 240 | 0.230 |
Why?
|
| Fuzzy Logic | 1 | 2025 | 16 | 0.230 |
Why?
|
| Patient-Centered Care | 2 | 2019 | 221 | 0.220 |
Why?
|
| Research Personnel | 2 | 2023 | 78 | 0.220 |
Why?
|
| Medical Marijuana | 1 | 2025 | 9 | 0.220 |
Why?
|
| Pyridones | 1 | 2025 | 66 | 0.220 |
Why?
|
| Self Report | 2 | 2025 | 328 | 0.220 |
Why?
|
| HIV Seroprevalence | 2 | 2018 | 9 | 0.220 |
Why?
|
| Models, Theoretical | 5 | 2021 | 494 | 0.210 |
Why?
|
| Quality of Life | 3 | 2024 | 1776 | 0.210 |
Why?
|
| Phylogeny | 6 | 2020 | 1268 | 0.210 |
Why?
|
| Qualitative Research | 4 | 2024 | 346 | 0.210 |
Why?
|
| Public Health | 4 | 2023 | 152 | 0.210 |
Why?
|
| Hospitals, Rural | 1 | 2004 | 8 | 0.210 |
Why?
|
| Time Factors | 4 | 2019 | 5380 | 0.200 |
Why?
|
| Ethics, Medical | 1 | 2006 | 291 | 0.200 |
Why?
|
| Physicians | 2 | 2025 | 668 | 0.200 |
Why?
|
| Occupational Health | 2 | 2014 | 40 | 0.200 |
Why?
|
| Health Risk Behaviors | 2 | 2020 | 6 | 0.200 |
Why?
|
| Anal Canal | 3 | 2022 | 92 | 0.190 |
Why?
|
| Narcotic Antagonists | 1 | 2024 | 170 | 0.190 |
Why?
|
| Otolaryngology | 3 | 2016 | 55 | 0.190 |
Why?
|
| Vaccination | 3 | 2022 | 303 | 0.190 |
Why?
|
| Herpesvirus 2, Human | 2 | 2015 | 20 | 0.190 |
Why?
|
| Internal Medicine | 1 | 2006 | 327 | 0.190 |
Why?
|
| Patient Transfer | 1 | 2004 | 107 | 0.190 |
Why?
|
| Sexual Health | 1 | 2023 | 20 | 0.190 |
Why?
|
| Mental Health | 1 | 2024 | 187 | 0.180 |
Why?
|
| Smartphone | 3 | 2019 | 52 | 0.180 |
Why?
|
| Quality Indicators, Health Care | 1 | 2004 | 151 | 0.180 |
Why?
|
| Population Surveillance | 2 | 2022 | 212 | 0.180 |
Why?
|
| Urinary Bladder Diseases | 1 | 2022 | 40 | 0.180 |
Why?
|
| Vulnerable Populations | 2 | 2020 | 90 | 0.180 |
Why?
|
| Data Collection | 2 | 2014 | 370 | 0.180 |
Why?
|
| Infectious Disease Medicine | 1 | 2021 | 8 | 0.180 |
Why?
|
| Homicide | 1 | 2022 | 53 | 0.180 |
Why?
|
| Capacity Building | 1 | 2021 | 12 | 0.170 |
Why?
|
| Rhinitis | 2 | 2017 | 183 | 0.170 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 45 | 0.170 |
Why?
|
| Human papillomavirus 18 | 2 | 2022 | 22 | 0.170 |
Why?
|
| Focus Groups | 3 | 2023 | 184 | 0.170 |
Why?
|
| Software | 2 | 2023 | 669 | 0.170 |
Why?
|
| Sinusitis | 2 | 2017 | 212 | 0.170 |
Why?
|
| Prospective Studies | 4 | 2023 | 4546 | 0.170 |
Why?
|
| San Francisco | 1 | 2020 | 25 | 0.170 |
Why?
|
| Emtricitabine | 1 | 2020 | 10 | 0.170 |
Why?
|
| Human papillomavirus 16 | 2 | 2022 | 45 | 0.160 |
Why?
|
| DNA, Viral | 2 | 2018 | 234 | 0.160 |
Why?
|
| Health Education | 2 | 2019 | 105 | 0.160 |
Why?
|
| Sex Characteristics | 1 | 2023 | 334 | 0.160 |
Why?
|
| Probability | 1 | 2021 | 352 | 0.160 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 168 | 0.160 |
Why?
|
| Methamphetamine | 1 | 2022 | 104 | 0.160 |
Why?
|
| Mentoring | 1 | 2021 | 31 | 0.160 |
Why?
|
| Rural Health Services | 1 | 2020 | 16 | 0.160 |
Why?
|
| Natural Language Processing | 1 | 2021 | 42 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2025 | 618 | 0.160 |
Why?
|
| Suicide | 1 | 2022 | 163 | 0.160 |
Why?
|
| Universities | 2 | 2019 | 150 | 0.160 |
Why?
|
| Intensive Care Units | 1 | 2004 | 450 | 0.150 |
Why?
|
| Psychological Theory | 1 | 2020 | 23 | 0.150 |
Why?
|
| Psychotherapy, Brief | 1 | 2020 | 13 | 0.150 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 3814 | 0.150 |
Why?
|
| Social Norms | 1 | 2019 | 15 | 0.150 |
Why?
|
| Marijuana Smoking | 2 | 2018 | 28 | 0.150 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 63 | 0.150 |
Why?
|
| Forecasting | 1 | 2020 | 288 | 0.150 |
Why?
|
| Coronary Vessels | 1 | 2021 | 175 | 0.150 |
Why?
|
| Treatment Outcome | 5 | 2020 | 9070 | 0.150 |
Why?
|
| Public Health Practice | 1 | 2019 | 11 | 0.150 |
Why?
|
| Eligibility Determination | 1 | 2019 | 39 | 0.150 |
Why?
|
| Patient Navigation | 1 | 2019 | 16 | 0.140 |
Why?
|
| Professional-Patient Relations | 1 | 2019 | 48 | 0.140 |
Why?
|
| Genetic Testing | 1 | 2023 | 564 | 0.140 |
Why?
|
| Housing | 1 | 2019 | 50 | 0.140 |
Why?
|
| Health Expenditures | 1 | 2020 | 98 | 0.140 |
Why?
|
| Awareness | 1 | 2019 | 89 | 0.140 |
Why?
|
| Community Health Centers | 1 | 2020 | 119 | 0.140 |
Why?
|
| Equipment Design | 2 | 2018 | 411 | 0.140 |
Why?
|
| Geographic Mapping | 1 | 2018 | 14 | 0.140 |
Why?
|
| Truth Disclosure | 1 | 2019 | 73 | 0.140 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2018 | 24 | 0.140 |
Why?
|
| Sex Distribution | 1 | 2018 | 174 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 2 | 2018 | 891 | 0.140 |
Why?
|
| Organizational Affiliation | 1 | 2018 | 6 | 0.140 |
Why?
|
| Demography | 1 | 2018 | 190 | 0.140 |
Why?
|
| China | 2 | 2009 | 264 | 0.130 |
Why?
|
| Models, Statistical | 3 | 2019 | 584 | 0.130 |
Why?
|
| Unemployment | 1 | 2017 | 11 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 494 | 0.130 |
Why?
|
| Personhood | 1 | 2017 | 16 | 0.130 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2017 | 9 | 0.130 |
Why?
|
| New York City | 3 | 2025 | 69 | 0.130 |
Why?
|
| Police | 1 | 2017 | 25 | 0.130 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 46 | 0.130 |
Why?
|
| Health Services Administration | 1 | 2017 | 2 | 0.130 |
Why?
|
| Internship and Residency | 1 | 2006 | 1074 | 0.130 |
Why?
|
| Financing, Organized | 1 | 2017 | 12 | 0.130 |
Why?
|
| Genotype | 2 | 2018 | 1866 | 0.130 |
Why?
|
| Hepatitis C | 1 | 2019 | 181 | 0.130 |
Why?
|
| Personal Satisfaction | 1 | 2017 | 65 | 0.120 |
Why?
|
| Physician-Patient Relations | 2 | 2016 | 561 | 0.120 |
Why?
|
| Community Health Services | 1 | 2018 | 79 | 0.120 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 73 | 0.120 |
Why?
|
| Transsexualism | 1 | 2016 | 24 | 0.120 |
Why?
|
| Calcium | 1 | 2021 | 1173 | 0.120 |
Why?
|
| Likelihood Functions | 1 | 2016 | 256 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2017 | 119 | 0.120 |
Why?
|
| Cues | 1 | 2017 | 186 | 0.120 |
Why?
|
| Cocaine-Related Disorders | 1 | 2016 | 39 | 0.120 |
Why?
|
| Reimbursement, Incentive | 1 | 2016 | 36 | 0.120 |
Why?
|
| Medicaid | 1 | 2018 | 245 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2019 | 806 | 0.110 |
Why?
|
| Instinct | 1 | 2015 | 2 | 0.110 |
Why?
|
| Crime Victims | 1 | 2016 | 55 | 0.110 |
Why?
|
| Treponema pallidum | 1 | 2015 | 8 | 0.110 |
Why?
|
| Psychotherapy, Group | 1 | 2015 | 37 | 0.110 |
Why?
|
| Bayes Theorem | 1 | 2016 | 403 | 0.110 |
Why?
|
| Medicare | 1 | 2018 | 451 | 0.110 |
Why?
|
| Paris | 3 | 2019 | 5 | 0.110 |
Why?
|
| Ukraine | 3 | 2019 | 22 | 0.110 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 150 | 0.110 |
Why?
|
| Needs Assessment | 1 | 2016 | 167 | 0.110 |
Why?
|
| Trauma, Nervous System | 1 | 2014 | 10 | 0.110 |
Why?
|
| Atlanto-Occipital Joint | 1 | 2014 | 4 | 0.110 |
Why?
|
| Atlanto-Axial Joint | 1 | 2014 | 13 | 0.110 |
Why?
|
| Neoplasms | 2 | 2021 | 3168 | 0.100 |
Why?
|
| Trauma Severity Indices | 1 | 2014 | 46 | 0.100 |
Why?
|
| Health Services | 2 | 2019 | 53 | 0.100 |
Why?
|
| Ligaments, Articular | 1 | 2014 | 39 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 504 | 0.100 |
Why?
|
| Causality | 1 | 2014 | 82 | 0.100 |
Why?
|
| Cognition | 1 | 2019 | 625 | 0.100 |
Why?
|
| Community Participation | 1 | 2014 | 39 | 0.100 |
Why?
|
| Craniocerebral Trauma | 1 | 2014 | 52 | 0.100 |
Why?
|
| Albuterol | 1 | 2014 | 35 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 2465 | 0.100 |
Why?
|
| Interdisciplinary Communication | 1 | 2014 | 133 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 1909 | 0.100 |
Why?
|
| Bronchodilator Agents | 1 | 2014 | 70 | 0.100 |
Why?
|
| Thoracic Vertebrae | 1 | 2014 | 88 | 0.100 |
Why?
|
| Lactic Acid | 1 | 2014 | 93 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 916 | 0.100 |
Why?
|
| Harm Reduction | 2 | 2024 | 28 | 0.100 |
Why?
|
| Drama | 1 | 2013 | 7 | 0.100 |
Why?
|
| Delphi Technique | 1 | 2013 | 135 | 0.100 |
Why?
|
| Fentanyl | 2 | 2025 | 84 | 0.100 |
Why?
|
| Case Management | 2 | 2024 | 28 | 0.100 |
Why?
|
| Trauma Centers | 1 | 2014 | 174 | 0.100 |
Why?
|
| Joint Instability | 1 | 2014 | 98 | 0.100 |
Why?
|
| Machine Learning | 3 | 2021 | 346 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2016 | 2889 | 0.090 |
Why?
|
| Occupations | 1 | 2012 | 24 | 0.090 |
Why?
|
| Telephone | 1 | 2012 | 36 | 0.090 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2012 | 24 | 0.090 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2012 | 10 | 0.090 |
Why?
|
| Prejudice | 1 | 2012 | 49 | 0.090 |
Why?
|
| Spouses | 1 | 2012 | 31 | 0.090 |
Why?
|
| Leadership | 1 | 2014 | 149 | 0.090 |
Why?
|
| Child | 2 | 2020 | 7273 | 0.090 |
Why?
|
| Tracheostomy | 1 | 2012 | 45 | 0.090 |
Why?
|
| Treatment Failure | 1 | 2012 | 291 | 0.090 |
Why?
|
| Extramarital Relations | 1 | 2011 | 1 | 0.090 |
Why?
|
| Coitus | 1 | 2011 | 19 | 0.090 |
Why?
|
| Epidemiologic Research Design | 1 | 2011 | 23 | 0.090 |
Why?
|
| Marital Status | 1 | 2011 | 43 | 0.090 |
Why?
|
| Social Class | 1 | 2012 | 142 | 0.080 |
Why?
|
| Sodium, Dietary | 1 | 2011 | 9 | 0.080 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 233 | 0.080 |
Why?
|
| Hyponatremia | 1 | 2011 | 30 | 0.080 |
Why?
|
| Health Care Coalitions | 1 | 2011 | 9 | 0.080 |
Why?
|
| Community-Institutional Relations | 1 | 2011 | 31 | 0.080 |
Why?
|
| Occupational Diseases | 1 | 2011 | 52 | 0.080 |
Why?
|
| Length of Stay | 1 | 2014 | 820 | 0.080 |
Why?
|
| Women's Health Services | 1 | 2009 | 14 | 0.080 |
Why?
|
| Sodium | 1 | 2011 | 328 | 0.080 |
Why?
|
| Linear Models | 2 | 2025 | 413 | 0.080 |
Why?
|
| Pediatrics | 1 | 2014 | 378 | 0.080 |
Why?
|
| Spinal Fusion | 1 | 2014 | 347 | 0.070 |
Why?
|
| Public Sector | 1 | 2009 | 13 | 0.070 |
Why?
|
| Molecular Epidemiology | 2 | 2020 | 57 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 381 | 0.070 |
Why?
|
| Registries | 1 | 2014 | 995 | 0.070 |
Why?
|
| HIV Serosorting | 2 | 2018 | 4 | 0.070 |
Why?
|
| Social Environment | 2 | 2020 | 194 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 7039 | 0.070 |
Why?
|
| Vaginal Discharge | 1 | 2007 | 2 | 0.070 |
Why?
|
| Diet | 1 | 2011 | 461 | 0.070 |
Why?
|
| Warts | 1 | 2007 | 12 | 0.070 |
Why?
|
| Ulcer | 1 | 2007 | 38 | 0.070 |
Why?
|
| Hospitals, University | 1 | 2008 | 188 | 0.070 |
Why?
|
| Infant | 1 | 2014 | 3156 | 0.070 |
Why?
|
| Therapeutic Irrigation | 1 | 2007 | 73 | 0.070 |
Why?
|
| Mucous Membrane | 1 | 2007 | 82 | 0.060 |
Why?
|
| Immunoglobulin A | 1 | 2007 | 89 | 0.060 |
Why?
|
| Vitamin D | 1 | 2008 | 272 | 0.060 |
Why?
|
| Diketopiperazines | 1 | 2025 | 6 | 0.060 |
Why?
|
| Multilevel Analysis | 1 | 2025 | 25 | 0.060 |
Why?
|
| Conflict of Interest | 1 | 2006 | 69 | 0.060 |
Why?
|
| Drug Trafficking | 1 | 2025 | 2 | 0.060 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 752 | 0.060 |
Why?
|
| Poisson Distribution | 1 | 2025 | 47 | 0.060 |
Why?
|
| Hospitalization | 3 | 2022 | 924 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2007 | 883 | 0.060 |
Why?
|
| Asthma | 1 | 2014 | 1039 | 0.060 |
Why?
|
| Law Enforcement | 1 | 2025 | 11 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 465 | 0.060 |
Why?
|
| Research Design | 2 | 2020 | 620 | 0.060 |
Why?
|
| Interprofessional Relations | 1 | 2006 | 116 | 0.060 |
Why?
|
| Injections | 1 | 2025 | 121 | 0.060 |
Why?
|
| Case Managers | 1 | 2024 | 3 | 0.050 |
Why?
|
| Pain | 1 | 2007 | 412 | 0.050 |
Why?
|
| Alcoholic Beverages | 1 | 2024 | 12 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 1 | 2004 | 113 | 0.050 |
Why?
|
| Spatial Analysis | 1 | 2024 | 11 | 0.050 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2004 | 6 | 0.050 |
Why?
|
| Iowa | 1 | 2004 | 33 | 0.050 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2004 | 27 | 0.050 |
Why?
|
| Hospitals, Community | 1 | 2004 | 33 | 0.050 |
Why?
|
| Pheochromocytoma | 1 | 2004 | 53 | 0.050 |
Why?
|
| Patient Admission | 1 | 2004 | 118 | 0.050 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2004 | 83 | 0.050 |
Why?
|
| Midwestern United States | 1 | 2023 | 90 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2007 | 1925 | 0.050 |
Why?
|
| Genes, Viral | 1 | 2023 | 101 | 0.050 |
Why?
|
| Parental Consent | 1 | 2023 | 36 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3450 | 0.050 |
Why?
|
| Employment | 1 | 2022 | 54 | 0.040 |
Why?
|
| Policy | 1 | 2022 | 41 | 0.040 |
Why?
|
| Cause of Death | 1 | 2022 | 271 | 0.040 |
Why?
|
| Lost to Follow-Up | 1 | 2021 | 15 | 0.040 |
Why?
|
| Needle Sharing | 1 | 2020 | 15 | 0.040 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2020 | 1 | 0.040 |
Why?
|
| Informed Consent | 1 | 2023 | 276 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 204 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2013 | 573 | 0.040 |
Why?
|
| Parents | 1 | 2023 | 292 | 0.040 |
Why?
|
| Health Personnel | 1 | 2022 | 234 | 0.040 |
Why?
|
| Florida | 1 | 2019 | 60 | 0.040 |
Why?
|
| Anxiety | 1 | 2022 | 336 | 0.040 |
Why?
|
| Mississippi | 1 | 2019 | 4 | 0.040 |
Why?
|
| New Orleans | 1 | 2019 | 7 | 0.040 |
Why?
|
| Homophobia | 1 | 2019 | 4 | 0.040 |
Why?
|
| Africa | 1 | 2019 | 109 | 0.040 |
Why?
|
| Emotions | 1 | 2023 | 368 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2019 | 43 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 655 | 0.040 |
Why?
|
| Knowledge | 1 | 2019 | 30 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 338 | 0.040 |
Why?
|
| Europe, Eastern | 1 | 2018 | 3 | 0.040 |
Why?
|
| Mouth | 1 | 2018 | 45 | 0.040 |
Why?
|
| New York | 1 | 2018 | 78 | 0.030 |
Why?
|
| Penis | 1 | 2018 | 61 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 71 | 0.030 |
Why?
|
| Asia | 1 | 2018 | 108 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 393 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2018 | 147 | 0.030 |
Why?
|
| Economic Competition | 1 | 2017 | 12 | 0.030 |
Why?
|
| Mobile Applications | 1 | 2018 | 78 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2017 | 29 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 651 | 0.030 |
Why?
|
| Exercise | 1 | 2020 | 353 | 0.030 |
Why?
|
| London | 1 | 2016 | 15 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2016 | 78 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2015 | 34 | 0.030 |
Why?
|
| Preventive Health Services | 1 | 2015 | 37 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 248 | 0.030 |
Why?
|
| Algorithms | 1 | 2023 | 1948 | 0.030 |
Why?
|
| Family | 1 | 2016 | 319 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 538 | 0.030 |
Why?
|
| Ipratropium | 1 | 2014 | 18 | 0.030 |
Why?
|
| Spirometry | 1 | 2014 | 77 | 0.030 |
Why?
|
| Forced Expiratory Volume | 1 | 2014 | 136 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2017 | 618 | 0.020 |
Why?
|
| Prednisone | 1 | 2014 | 242 | 0.020 |
Why?
|
| Safety Management | 1 | 2012 | 52 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 753 | 0.020 |
Why?
|
| Animals | 1 | 2011 | 27973 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2012 | 155 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2014 | 360 | 0.020 |
Why?
|
| Pressure | 1 | 2012 | 165 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2012 | 70 | 0.020 |
Why?
|
| Middle East | 1 | 2011 | 19 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 278 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2011 | 24 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2011 | 46 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1727 | 0.020 |
Why?
|
| Seasons | 1 | 2011 | 239 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2012 | 404 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 1529 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2012 | 418 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2009 | 154 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 1905 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 648 | 0.020 |
Why?
|
| Mobile Health Units | 1 | 2007 | 12 | 0.020 |
Why?
|
| Tracheotomy | 1 | 2007 | 18 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2008 | 941 | 0.010 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2004 | 107 | 0.010 |
Why?
|
| Inflammation | 1 | 2008 | 1049 | 0.010 |
Why?
|
| Acute Disease | 1 | 2004 | 838 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2004 | 258 | 0.010 |
Why?
|
| Pregnancy | 1 | 2004 | 3128 | 0.010 |
Why?
|